July 15, 2020
From mRNA vaccines entering clinical trials, to peptide-based vaccines and using molecular farming to scale vaccine production, the COVID-19 pandemic is pushing new and emerging nanotechnologies into the frontlines and the headlines.
August 31, 2021
UC San Diego researchers developed first-of-their-kind lung organoids that include all cell types that make up the organ, allowing for “Phase 0” testing of new treatments for respiratory infections such as COVID-19.
September 8, 2021
SARS-CoV, MERS-CoV, influenza, measles, and the rhinoviruses that cause the common cold can all spread via aerosols that can build up in indoor air and linger for hours, an international, interdisciplinary team of researchers has reported in a review published in the journal Science.
September 7, 2021
Nanoengineers at the University of California San Diego have developed COVID-19 vaccine candidates that can take the heat. Their key ingredients? Viruses from plants or bacteria.
August 11, 2021
Part of UC San Diego’s Return to Learn program, wastewater screening helped prevent outbreaks by detecting 85 percent of cases early, allowing for timely testing, contact tracing and isolation.
October 1, 2020
UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.
April 1, 2021
UC San Diego students will participate in nationwide clinical trial to assess if COVID-19 vaccination prevents infection and reduces risk of transmission.
August 5, 2020
The National Institutes of Health will soon launch a Phase II clinical trial to evaluate the safety and efficacy of potential new therapeutics for COVID-19, including the use of investigational synthetic monoclonal antibodies. Davey Smith of UC San Diego is the protocol chair and answers questions.
January 16, 2024
Advanced research and leading-edge tracing technology show infection prevention safety measures were effective in stopping viral spread at UC San Diego Health.
June 21, 2022
COVID-19 rebound following Paxlovid treatment likely due to insufficient drug exposure, UC San Diego researchers find after showing rebound patient did not show drug resistance or impaired immunity.
